Compare Crocs, Inc. (CROX) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Moderna, Inc. — how do they compare? Crocs, Inc. trades at $114.98 (market cap $5.60B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 14× Crocs, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, Crocs, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and Moderna, Inc. for 59 Days on average.
| CROX | MRNA | |
|---|---|---|
Market Cap | $5.60B | $78.65B |
Volume | 1,026,773 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $225.00 |
52-Week Low | $73.39 | $22.36 |
Typical Hold Time | 96 Days | 59 Days |
Enterprise Value | $7.12B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $116.84, up 1.42% with bearish technical signals but strong fundamentals including a low P/E of 10.37 and robust ROE of 42.3%. Recent earnings beats and a $136.78 analyst price target suggest upside potential despite negative net income in 2025. The company maintains solid cash flow generation and brand innovation focus.
The outlook remains positive with earnings momentum and valuation appeal, though risks include consumer spending volatility and HEYDUDE brand integration challenges. Analyst consensus leans bullish with 51% buy ratings, supporting potential recovery from current levels if execution improves.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
